Invivyd Stock Quote IVVD - Stock Price, News, Charts, Message Board, Trades

Empower your portfolio: Real-time discussions and actionable trading ideas.

Premium

Current Price

0.435

Bid

0.4311

Ask

0.435

Volume

2,484

0.00 Day's Range 0.00

0.38 52 Week Range 5.195

Market Cap

52.033M

Previous Close

0.4183

Open

Last Trade

454

0.435

(formt)

Last Trade Time

07:02:44

Financial Volume

VWAP

Average Volume (3m)

1,135,361

Shares Outstanding

119,616,035

Dividend Yield

PE Ratio

-2.79

Earnings Per Share (EPS)

-1.66

Revenue

Net Profit

-198.64M

Invivyd Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of antibody-based solutions for infectious diseases with pandemic potential. The company is developing antibodies to transcend the limits of naturally occurring immunity and ... Invivyd Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of antibody-based solutions for infectious diseases with pandemic potential. The company is developing antibodies to transcend the limits of naturally occurring immunity and provide superior protection from viral diseases, beginning with COVID-19. The company's lead product candidate, ADG20 is developed for the treatment and prevention of coronavirus disease which has demonstrated clinically meaningful results in global Phase 3 clinical trials against multiple variants of concern for the prevention and treatment of COVID-19. Show more

Sector

Biological Pds,ex Diagnstics

Industry

Biological Pds,ex Diagnstics

Website

invivyd.com

Headquarters

Wilmington, Delaware, USA

Founded

Invivyd Inc is listed in the Biological Pds,ex Diagnstics sector of the NASDAQ with ticker IVVD. The last closing price for Invivyd was $0.42. Over the last year, Invivyd shares have traded in a share price range of $ 0.38 to $ 5.195.

Invivyd currently has 119,616,035 shares outstanding. The market capitalization of Invivyd is $50.04 million. Invivyd has a price to earnings ratio (PE ratio) of -2.79.

Form 8-K - Current report

Invivyd Announces Continued Neutralizing Activity of PEMGARDA™ (pemivibart) Against Dominant SARS-CoV-2 Variant XEC

New in vitro neutralization data show continued, consistent neutralizing activity of PEMGARDA™ (pemivibart) against XEC Centers for Disease Control reports XEC and KP.3.1.1 (previously disclosed...

Form 8-K - Current report

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

Invivyd Reports Third Quarter 2024 Financial Results and Recent Business Highlights

Q3 2024 PEMGARDA™ (pemivibart) net product revenue of $9.3 million; Invivyd ended Q3 2024 with $106.9 million in cash and cash equivalentsTargets near-term (1H 2025) profitability with existing...

Invivyd Announces New England Journal of Medicine Publishes Letter to the Editor Highlighting Immunobridging Pathway Leading to PEMGARDA™ (pemivibart) Emergency Use Authorization; Comments on Adjacent Third-Party Letter to the Editor

The New England Journal of Medicine (NEJM) Letter to the Editor outlines the novel, rapid immunobridging authorization pathway for PEMGARDA and provides an updated correlate of protection curve...

Invivyd Announces Preprints Conveying CANOPY Phase 3 Clinical Trial Data Including Long-Term Protection Versus Recent JN.1 Sublineages at Low Residual Titers, and Describing a Novel Approach for Predicting Monoclonal Antibody Activity Were Uploaded to MedR

CANOPY manuscript preprint includes six-month off-drug follow-up period that highlighted strong protection by pemivibart versus placebo in the immunocompetent Cohort B during KP.3 and KP.3.1.1...

Period	Change	Change %	Open	High	Low	Avg. Daily Vol	VWAP
1	-0.0045	-1.02389078498	0.4395	0.4611	0.38	536676	0.40677433	CS
4	-0.1152	-20.9378407852	0.5502	0.59	0.38	1855968	0.45591412	CS
12	-0.455	-51.1235955056	0.89	1.07	0.38	1135361	0.55213329	CS
26	-0.795	-64.6341463415	1.23	1.455	0.38	738813	0.70959931	CS
52	-4.025	-90.2466367713	4.46	5.195	0.38	733468	1.80944269	CS
156	-4.265	-90.7446808511	4.7	5.195	0.38	603153	2.29921468	CS
260	-4.265	-90.7446808511	4.7	5.195	0.38	603153	2.29921468	CS

IVVD - Frequently Asked Questions (FAQ)

What is the current Invivyd share price?

The current share price of Invivyd is $ 0.435

How many Invivyd shares are in issue?

Invivyd has 119,616,035 shares in issue

What is the market cap of Invivyd?

The market capitalisation of Invivyd is USD 50.04M

What is the 1 year trading range for Invivyd share price?

Invivyd has traded in the range of $ 0.38 to $ 5.195 during the past year

What is the PE ratio of Invivyd?

The price to earnings ratio of Invivyd is -2.79

What is the reporting currency for Invivyd?

Invivyd reports financial results in USD

What is the latest annual profit for Invivyd?

The latest annual profit of Invivyd is USD -198.64M

What is the registered address of Invivyd?

The registered address for Invivyd is CORPORATION TRUST CENTER, 1209 ORANGE ST, NEW CASTLE, WILMINGTON, DELAWARE, 19801

What is the Invivyd website address?

The website address for Invivyd is invivyd.com

Which industry sector does Invivyd operate in?

Invivyd operates in the BIOLOGICAL PDS,EX DIAGNSTICS sector

Most Active
% Gainers
% Losers

Symbol	Price	Vol.
STBXStarBox Group Holdings Ltd	$ 0.865 (69.57%)	7.66M
IROHIron Horse Acquisition Corporation	$ 16.45 (58.94%)	6
OSTOstin Technology Group Company Ltd	$ 3.83 (58.26%)	4.35M
CRWSCrown Crafts Inc	$ 6.99 (55.68%)	1
IZTCInvizyne Technologies Inc	$ 18.00 (51.39%)	6
MDXGMiMedx Group Inc	$ 5.11 (-43.41%)	128
IROQIF Bancorp Inc	$ 14.01 (-41.89%)	3
LRFCLogan Ridge Finance Corporation	$ 14.01 (-41.65%)	14
HYZNHyzon Motors Inc	$ 0.5001 (-35.22%)	91.16k
BCALCalifornia BanCorp	$ 10.01 (-32.82%)	19
ACONAclarion Inc	$ 0.0564 (30.56%)	66.65M
BTAIBioXcel Therapeutics Inc	$ 0.4053 (6.71%)	15.82M
ATXIAvenue Therapeutics Inc	$ 1.97 (7.07%)	14.2M
STBXStarBox Group Holdings Ltd	$ 0.865 (69.57%)	7.66M
EVAXEvaxion Biotech AS	$ 5.40 (48.35%)	7.05M